KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) EPS (Basic) (2020 - 2025)

Historic EPS (Basic) for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to -$0.36.

  • Recursion Pharmaceuticals' EPS (Basic) fell 588.24% to -$0.36 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.84, marking a year-over-year decrease of 1870.97%. This contributed to the annual value of -$1.69 for FY2024, which is 701.99% down from last year.
  • Per Recursion Pharmaceuticals' latest filing, its EPS (Basic) stood at -$0.36 for Q3 2025, which was down 588.24% from -$0.41 recorded in Q2 2025.
  • Recursion Pharmaceuticals' EPS (Basic)'s 5-year high stood at -$0.28 during Q3 2021, with a 5-year trough of -$1.33 in Q1 2021.
  • Its 5-year average for EPS (Basic) is -$0.44, with a median of -$0.38 in 2022.
  • As far as peak fluctuations go, Recursion Pharmaceuticals' EPS (Basic) plummeted by 5647.06% in 2021, and later soared by 7518.8% in 2022.
  • Recursion Pharmaceuticals' EPS (Basic) (Quarter) stood at -$0.39 in 2021, then grew by 23.08% to -$0.3 in 2022, then crashed by 40.0% to -$0.42 in 2023, then crashed by 55.34% to -$0.65 in 2024, then soared by 44.82% to -$0.36 in 2025.
  • Its last three reported values are -$0.36 in Q3 2025, -$0.41 for Q2 2025, and -$0.5 during Q1 2025.